Overview

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
Phase:
PHASE2
Details
Lead Sponsor:
Kyverna Therapeutics